Siren Biotechnology, a gene therapy company pioneering Universal AAV Immuno-Gene Therapies for Cancer™, announced today that the California Institute for Regenerative Medicine (CIRM) has awarded the company a $4M translational research grant to support the development of novel AAV immuno-gene therapies for cancer.
Nicole Paulk, PhD, is the lead inventor.